TrialBritish journal of clinical pharmacology2022

Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.

Li Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.